Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.54 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.41 |
| ▸ | BCR | P11274 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29756936 | 1.00 | ESR1 (0.54) | ESR1ESR2CYP26A1MIFKDM4E | |
| SCHEMBL7624883 | 0.89 | ESR1 (0.60) | ESR1ESR2CYP26A1MIFKDM4E | |
| SCHEMBL27321349 | 0.76 | TLR9 (0.42) | KDM4EALDH1A1MAPTSIGMAR1 | |
| SCHEMBL20179676 | 0.76 | HTR2C (0.40) | ESR1 | |
| SCHEMBL20179672 | 0.76 | HTR2C (0.40) | ESR1 | |
| SCHEMBL20179795 | 0.76 | ESR2 (0.46) | ESR1ESR2CYP26A1MIFKDM4E | |
| Hydrochloric Acid SCHEMBL20165096 | 0.75 | HTR2C (0.39) | ESR1 | |
| Hydrochloric Acid SCHEMBL20165098 | 0.75 | HTR2C (0.39) | ESR1 | |
| Hydrochloric Acid SCHEMBL29756772 | 0.75 | HTR2C (0.39) | ESR1 | |
| SCHEMBL29632065 | 0.75 | ESR1 (0.46) | ESR1ESR2CYP26A1MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541809-B1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI SA (FR) | 2025-06-25 | — | — | EP | disclosed |
| US-20220204488-A1 | Novel Substituted N-(3-Fluoropropyl)-Pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof | SANOFI (FR) | 2022-06-30 | — | — | US | disclosed |
| US-20220204488-A1 | Novel Substituted N-(3-Fluoropropyl)-Pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof | SANOFI (FR) | 2022-06-30 | — | — | US | disclosed |
| US-11149031-B2 | Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2021-10-19 | — | — | US | disclosed |
| US-11149031-B2 | Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2021-10-19 | — | — | US | disclosed |
| US-20200361918-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (FR) | 2020-11-19 | — | — | US | disclosed |
| US-20200361918-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (FR) | 2020-11-19 | — | — | US | disclosed |
| EP-3541809-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018091153-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018091153-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361918-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | ESR1, CYP19A1, ESR2 | ESR1 1/4885ESR2 3/4885CYP26A1 155/4885 |
| US-11149031-B2 | Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | ESR1, CYP19A1, ESR2 | ESR1 1/4885ESR2 3/4885CYP26A1 133/4885 |
| US-20220204488-A1 | Novel Substituted N-(3-Fluoropropyl)-Pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof | ESR1, CYP19A1, GPER1 | ESR1 1/4885ESR2 4/4885CYP26A1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.